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Summary 
Background 
Trial findings show cognitive behaviour therapy (CBT) and graded exercise therapy (GET) can be 
effective treatments for chronic fatigue syndrome, but patients' organisations have reported that 
these treatments can be harmful and favour pacing and specialist health care. We aimed to assess 
effectiveness and safety of all four treatments. 
 
Methods 
In our parallel-group randomised trial, patients meeting Oxford criteria for chronic fatigue syndrome 
were recruited from six secondary-care clinics in the UK and randomly allocated by computer-
generated sequence to receive specialist medical care (SMC) alone or with adaptive pacing therapy 
(APT), CBT, or GET. Primary outcomes were fatigue (measured by Chalder fatigue questionnaire 
score) and physical function (measured by short form-36 subscale score) up to 52 weeks after 
randomisation, and safety was assessed primarily by recording all serious adverse events, including 
serious adverse reactions to trial treatments. Primary outcomes were rated by participants, who 
were necessarily unmasked to treatment assignment; the statistician was masked to treatment 
assignment for the analysis of primary outcomes. We used longitudinal regression models to 
compare SMC alone with other treatments, APT with CBT, and APT with GET. The final analysis 
included all participants for whom we had data for primary outcomes. This trial is registered at 
http://isrctn.org, number ISRCTN54285094. 
 
Findings 
We recruited 641 eligible patients, of whom 160 were assigned to the APT group, 161 to the CBT 
group, 160 to the GET group, and 160 to the SMC-alone group. Compared with SMC alone, mean 
fatigue scores at 52 weeks were 3·4 (95% CI 1·8 to 5·0) points lower for CBT (p=0·0001) and 3·2 (1·7 
to 4·8) points lower for GET (p=0·0003), but did not differ for APT ;Ϭ·ϳ [−Ϭ·ϵ to Ϯ·ϯ] poiŶts loǁer; 
p=0·38). Compared with SMC alone, mean physical function scores were 7·1 (2·0 to 12·1) points 
higher for CBT (p=0·0068) and 9·4 (4·4 to 14·4) points higher for GET (p=0·0005), but did not differ 
for APT ;ϯ·ϰ [−ϭ·ϲ to ϴ·ϰ] points lower; p=0·18). Compared with APT, CBT and GET were associated 
with less fatigue (CBT p=0·0027; GET p=0·0059) and better physical function (CBT p=0·0002; GET 
p<0·0001). Subgroup analysis of 427 participants meeting international criteria for chronic fatigue 
syndrome and 329 participants meeting London criteria for myalgic encephalomyelitis yielded 
equivalent results. Serious adverse reactions were recorded in two (1%) of 159 participants in the 
APT group, three (2%) of 161 in the CBT group, two (1%) of 160 in the GET group, and two (1%) of 
160 in the SMC-alone group. 
 
Interpretation 
CBT and GET can safely be added to SMC to moderately improve outcomes for chronic fatigue 
syndrome, but APT is not an effective addition. 
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Introduction 
Chronic fatigue syndrome is characterised by chronic disabling fatigue in the absence of an 
alternative diagnosis.1 Myalgic encephalomyelitis is thought by some researchers to be the same 
disorder and by others as different with separate diagnostic criteria.1,2 The prevalence of chronic 
fatigue syndrome is between 0·2% and 2·6% worldwide, dependent on the definition used.1 
Prognosis is poor if untreated.3 
Specific therapies can improve outcomes. The UK National Institute for Health and Clinical Excellence 
(NICE) recommend cognitive behaviour therapy (CBT) and graded exercise therapy (GET).2 Although 
this recommendation was supported by systematic reviews,4–7 supporting evidence remains 
restricted to small trials.4–7 Surveys by patients' organisations in the UK have reported that CBT and 
GET are sometimes harmful, and have recommended pacing and specialist health care.8,9 
We designed the pacing, graded activity, and cognitive behaviour therapy: a randomised evaluation 
(PACE) trial10 to compare pacing, defined as adaptive pacing therapy (APT), CBT, and GET, when 
added to specialist medical care (SMC) with SMC alone. We sought evidence of benefit and harm. 
We also aimed to compare APT against CBT and GET and examine these comparisons in subgroups 
satisfying different diagnostic criteria for chronic fatigue syndrome and myalgic encephalomyelitis. 
We postulated that CBT and GET would be more effective than would APT and SMC, and that APT 
would be more effective than SMC alone. 
 
 
Methods 
 
Study design and participants 
PACE was a parallel, four group, multicentre, randomised trial, with outcomes assessed up to 52 
weeks after randomisation for patients with chronic fatigue syndrome.10 We recruited 641 
participants from consecutive new outpatients attending six specialist chronic fatigue syndrome 
clinics in the UK National Health Service between March 18, 2005, and Nov 28, 2008, and completed 
outcome data collection in January, 2010. 
Several diagnostic criteria exist for chronic fatigue syndrome and myalgic encephalomyelitis.11–13 
We selected participants in accordance with Oxford criteria for chronic fatigue syndrome.11 These 
criteria require fatigue to be the main symptom, accompanied by significant disability, in the 
absence of an exclusionary medical or psychiatric diagnosis (psychosis, bipolar disorder, substance 
misuse, an organic brain disorder, or an eating disorder).11 All participants were medically assessed 
by the specialist clinic doctors to exclude alternative diagnoses.2,12 Research assessors used the 
structured clinical interview from the Diagnostic and Statistical Manual of Mental Disorders IV to 
diagnose exclusionary and comorbid psychiatric disorders (ie, mood and anxiety disorders).10,14 
Other eligibility criteria consisted of a bimodal score of 6 of 11 or more on the Chalder fatigue 
questionnaire15 and a score of 60 of 100 or less on the short form-36 physical function subscale.16 
11 months after the trial began, this requirement was changed from a score of 60 to a score of 65 to 
increase recruitment. 
We excluded patients who were younger than 18 years or at significant risk of self-harm, unable to 
attend hospital appointments, unable to speak and read English, had medical needs that made 
participation inappropriate, had previously received a trial treatment for their present illness at a 
PACE trial clinic (we initially excluded anyone who had received a trial treatment, but found the 
nature of treatment given elsewhere hard to establish).10 Participants were also assessed by 
international criteria for chronic fatigue syndrome,12 requiring four or more accompanying 
symptoms, and the London criteria13 for myalgic encephalomyelitis (version 2), requiring 
postexertional fatigue, poor memory and concentration, symptoms that fluctuate, and no primary 
depressive or anxiety disorder (interpreted as an absence of any such disorder). 
We obtained separate written informed consent for assessment and entry into the trial. The West 
Midlands Multicentre Research Ethics Committee (MREC 02/7/89) approved the study. 
 
Randomisation and masking 
Participants were allocated to treatment groups through the Mental Health and Neuroscience 
Clinical Trials Unit (London, UK), after baseline assessment and obtainment of consent. A database 
programmer undertook treatment allocation, independently of the trial team. The first three 
participants at each of the six clinics were allocated with straightforward randomisation. Thereafter 
allocation was stratified by centre, alternative criteria for chronic fatigue syndrome12 and myalgic 
encephalomyelitis,13 and depressive disorder (major or minor depressive episode or dysthymia),14 
with computer-generated probabilistic minimisation. Once notified of treatment allocation by the 
Clinical Trials Unit, the research assessor informed the participant and clinicians. One therapist was 
available for every therapy per centre, with few exceptions. Specialist medical care doctors were 
allocated by convenience. As with any therapy trial, participants, therapists, and doctors could not 
be masked to treatment allocation and it was also impractical to mask research assessors. The 
primary outcomes were rated by participants themselves. The statistician undertaking the analysis of 
primary outcomes was masked to treatment allocation. 
 
Procedures 
Panel 1 shows treatment strategies and webappendix p 1 shows characteristics of treating clinicians. 
Therapy leaders (one per therapy and with substantial experience in treatment of chronic fatigue 
syndrome) trained therapists until they were deemed competent to provide trial treatments. 
Individual therapy supervision was provided once every month, and by group every 3 months.24 All 
treatment sessions were recorded acoustically. Two independent clinicians, who were masked to 
allocated treatment, rated recordings of a randomly chosen sample of the tenth (or nearest) session 
of 62 (13%) of 480 participants (two sessions for every therapist, when available) for therapy type, 
adherence to the manual (7-point Likert scale), and therapeutic alliance between therapist and 
participant (7-point Likert scale). These clinicians recorded when masking had failed, such as when 
the treatment was mentioned by name. All doctors received training in specialist medical care, and 
we assessed competence and monitored manual adherence for most. We defined ten sessions of 
therapy or three sessions of specialist medical care alone as adequate treatment for the per-
protocol analysis. We recorded number of treatment sessions attended, active withdrawals from 
treatment, additional treatments received, and dropouts from follow-up. 
 
[Start panel 1] 
Panel 1 
Treatments provided 
Overview 
We standardised treatments by provision of manuals for doctors, therapists, and participants. At 
least three sessions of specialist medical care were offered to participants during the 12 months, and 
more were offered if clinically indicated. Up to 14 therapy sessions were offered during the first 23 
weeks; the first four were once a week and subsequently they were once every 2 weeks. An 
additional booster session was offered at 36 weeks. No other additional sessions were offered. Most 
treatments were delivered face-to-face but some were provided by telephone. Treatment was 
provided individually although participants could be accompanied if they wanted. 
Specialist medical care (SMC) 
SMC was provided by doctors with specialist experience in chronic fatigue syndrome (webappendix 
p 1). All participants were given a leaflet explaining the illness and the nature of this treatment. The 
manual was consistent with good medical practice, as presently recommended.2 Treatment 
consisted of an explanation of chronic fatigue syndrome, generic advice, such as to avoid extremes 
of activity and rest, specific advice on self-help, according to the particular approach chosen by the 
participant (if receiving SMC alone), and symptomatic pharmacotherapy (especially for insomnia, 
pain, and mood). 
Adaptive pacing therapy (APT) 
APT was based on the envelope theory of chronic fatigue syndrome.17,18 This theory regards 
chronic fatigue syndrome as an organic disease process that is not reversible by changes in 
behaviour and which results in a reduced and finite amount (envelope) of available energy. The aim 
of therapy was to achieve optimum adaptation to the illness, hence APT. This adaptation was 
achieved by helping the participant to plan and pace activity to reduce or avoid fatigue, achieve 
prioritised activities and provide the best conditions for natural recovery.13,17,18 Therapeutic 
strategies consisted of identifying links between activity and fatigue by use of a daily diary, with 
corresponding encouragement to plan activity to avoid exacerbations, developing awareness of early 
warnings of exacerbation, limiting demands and stress, regularly planning rest and relaxation, and 
alternating different types of activities, with advice not to undertake activities that demanded more 
than 70% of participants' perceived energy envelopes. Increased activities were encouraged, if the 
participant felt able, and as long as they did not exacerbate symptoms. 
Because this treatment had not been described in a manual, we created and piloted manuals for 
therapists and patients on the basis of previous descriptions,13,17 what pilot patients and clinicians 
reported as helpful, and with the advice of experienced therapists. Westcare and Action for ME 
helped in the design of the therapy and endorsed the final manuals.18 APT was provided by 
occupational therapists (webappendix p 1). 
Cognitive behaviour therapy (CBT) 
CBT was done on the basis of the fear avoidance theory of chronic fatigue syndrome. This theory 
regards chronic fatigue syndrome as being reversible and that cognitive responses (fear of engaging 
in activity) and behavioural responses (avoidance of activity) are linked and interact with 
physiological processes to perpetuate fatigue. The aim of treatment was to change the behavioural 
and cognitive factors assumed to be responsible for perpetuation of the participant's symptoms and 
disability. Therapeutic strategies guided participants to address unhelpful cognitions, including fears 
about symptoms or activity by testing them in behavioural experiments. These experiments 
consisted of establishing a baseline of activity and rest and a regular sleep pattern, and then making 
collaboratively planned gradual increases in both physical and mental activity. Furthermore, 
participants were helped to address social and emotional obstacles to improvement through 
problem-solving. Therapy manuals were based on manuals used in previous trials.19–21 CBT was 
delivered mainly by clinical psychologists and nurse therapists (webappendix p 1). 
Graded exercise therapy (GET) 
GET was done on the basis of deconditioning and exercise intolerance theories of chronic fatigue 
syndrome. These theories assume that the syndrome is perpetuated by reversible physiological 
changes of deconditioning and avoidance of activity. These changes result in the deconditioning 
being maintained and an increased perception of effort, leading to further inactivity. The aim of 
treatment was to help the participant gradually return to appropriate physical activities, reverse the 
deconditioning, and thereby reduce fatigue and disability. Therapeutic strategies consisted of 
establishment of a baseline of achievable exercise or physical activity, followed by a negotiated, 
incremental increase in the duration of time spent physically active. Target heart rate ranges were 
set when necessary to avoid overexertion, which eventually aimed at 30 min of light exercise five 
times a week. When this rate was achieved, the intensity and aerobic nature of the exercise was 
gradually increased, with participant feedback and mutual planning. The most commonly chosen 
exercise was walking. The therapy manual was based on that used in previous trials.22,23 GET was 
delivered by physiotherapists and one exercise physiologist (webappendix p 1). 
[End panel 1] 
 
We undertook assessments at baseline and 12 weeks (mid-therapy), 24 weeks (post-therapy), and 
52 weeks after randomisation. Primary outcomes were also assessed at the time of dropouts, and 
used when no other outcome data were available. The research assessors did the assessments, 
usually face-to-face in clinic. Most measures were self-rated by the participant. Because masking of 
research assessors to treatment allocation after randomisation was impractical, we relied on 
participant ratings to keep observer bias to a minimum. 
 
Outcomes 
The two participant-rated primary outcome measures were the Chalder fatigue questionnaire (Likert 
scoring 0, 1, 2, 3; range 0–33; lowest score is least fatigue)15 and the short form-36 physical function 
subscale (version 2; range 0–100; highest score is best function).16 Before outcome data were 
examined, we changed the original bimodal scoring of the Chalder fatigue questionnaire (range 0–
11) to Likert scoring to more sensitively test our hypotheses of effectiveness. The two primary 
outcome measures15,16 are valid and reliable and have been used in previous trials.4–7 
For safety outcomes, we included non-serious adverse events, serious adverse events, serious 
adverse reactions to trial treatments, serious deterioration, and active withdrawals from 
treatment.10 Adverse events were defined as any clinical change, disease, or disorder reported, 
whether or not related to treatment. Three scrutinisers (two physicians and one liaison psychiatrist 
who all specialised in chronic fatigue syndrome) reviewed all adverse events and reactions, 
independently from the trial team, and were masked to treatment group, to establish whether they 
were serious adverse events. Scrutinisers were then unmasked to treatment allocation to establish if 
any serious adverse events were serious adverse reactions. Serious deterioration in health was 
defined as any of the following outcomes: a short form-36 physical function score decrease of 20 or 
more between baseline and any two consecutive assessment interviews;16 scores of much or very 
much worse on the participant-rated clinical global impression change in overall health scale at two 
consecutive assessment interviews;25 withdrawal from treatment after 8 weeks because of a 
participant feeling worse; or a serious adverse reaction. 
For secondary outcomes, we used the clinical global impression scale to assess change from baseline 
in overall health.25 This 7-point scale was condensed into three categories: negative change (very 
much worse or much worse), minimum change (a little worse, no change, or a little better), and 
positive change (much better or very much better). We also assessed overall disability with the work 
and social adjustment scale,26 6-min walking ability (distance in m walked),27 Jenkins scale score for 
disturbed sleep,28 hospital anxiety and depression scale score,29 number of chronic fatigue 
syndrome symptoms, and individual symptoms of postexertional malaise and poor concentration or 
memory, as in the international criteria.12 These secondary outcomes were a subset of those 
specified in the protocol, selected in the statistical analysis plan as most relevant to this report. After 
participants had been told their treatment allocation, but before treatment began, they rated how 
logical their proposed treatment seemed and how confident they were that it would help them (5-
point Likert scale with moderately and extremely condensed into a positive response to help with 
interpretation). At 52 weeks, participants rated satisfaction with treatment received on a 7-point 
scale, condensed into three categories to aid interpretation (satisfied, neutral, or dissatisfied). 
 
Statistical analysis 
We calculated sample sizes assuming 60% response to CBT at 52 weeks, 50% response to GET, 25% 
response to APT, and 10% response to SMC.10 We assumed APT to be at least as effective as in 
previous trials of relaxation and flexibility therapies.20,22 For a two-sided test with 5% significance 
level and 90% power, we calculated that the number of participants needed to compare SMC with 
APT was 135, SMC with GET was 80, and SMC with CBT was 40. We increased group size to 150 per 
group to allow for 10% dropout, to provide equality between groups, and for secondary analyses. 
The statistical analysis plan was finalised, including changes to the original protocol, and was 
approved by the trial steering committee and the data monitoring and ethics committee before 
outcome data were examined. 
We used continuous scores for primary outcomes to allow a more straightforward interpretation of 
the individual outcomes, instead of the originally planned composite measures (50% change or 
meeting a threshold score).10,30 We prorated primary outcomes scales only when there were at 
most two items per scale missing (nine participants for Chalder fatigue questionnaire and 11 for 
short form-36). Prorating involved calculating the mean value of the item scores present and 
replacing the missing values with that score. 
We summarised continuous variables with mean (SD) or median (IQR) and categorical variables with 
frequencies and proportions. Differentiation of treatment compared independent ratings of therapy 
sessions with actual treatment. We calculated the inter-rater reliaďilitǇ ;κ and 95% CI) between the 
two assessors. We used Kruskal-Wallis tests for comparisons of therapy received, therapeutic 
alliance, and manual adherence. We compared categorical variables with Fisher's exact test. 
A clinically useful difference between the means of the primary outcomes was defined as 0·5 of the 
SD of these measures at baseline,31 equating to 2 points for Chalder fatigue questionnaire and 8 
points for short form-36. A secondary post-hoc analysis compared the proportions of participants 
who had improved between baseline and 52 weeks by 2 or more points of the Chalder fatigue 
questionnaire, 8 or more points of the short form-36, and improved on both. In another post-hoc 
analysis, we compared the proportions of participants who had scores of both primary outcomes 
within the normal range at 52 weeks. This range was defined as less than the mean plus 1 SD scores 
of adult attendees to UK general practice of 14·2 (+4·6) for fatigue (score of 18 or less) and equal to 
or aďoǀe the ŵeaŶ ŵiŶus ϭ “D sĐores of the UK ǁorkiŶg age populatioŶ of ϴϰ ;−ϮϰͿ for phǇsiĐal 
function (score of 60 or more).32,33 
We estimated differences between treatment groups for both primary outcomes with mixed linear 
regression models with Kenward-Roger adjusted standard errors. Covariates were treatment group, 
baseline value of outcome, time, and stratification factors (centre, present depressive disorder, and 
alternative criteria for chronic fatigue syndrome and myalgic encephalomyelitis; all as stratified at 
entry). Time by treatment interaction terms were included to allow extraction of contrasts at 52 
weeks. Models for the primary outcomes and the clinical global impression incorporated random 
intercepts and slopes over time by participant and main health-care practitioner (doctor or therapist 
who saw the participant most frequently, or, if equal, the first practitioner to see the participant) to 
allow for clustering of outcomes within practitioner. We calculated intraclass correlation 
coefficients, adjusted for baseline outcomes, using one-way random effects analysis of covariance at 
52 weeks within every treatment group. Unadjusted and Bonferroni corrected p values are provided 
for five comparisons for both primary outcomes. Comparisons of primary outcomes across 
treatment groups by alternative criteria for chronic fatigue syndrome and myalgic 
encephalomyelitis, and comorbid depressive disorder included the treatment by criteria or disorder 
interaction terms. Because some errors were made in stratification at randomisation, we used true 
status variables rather than status at stratification as covariates. 
We calculated adverse event and reaction rates by dividing the number of events by person-years of 
follow-up multiplied by 100, and compared rate differences (95% CI) between treatment groups. 
We analysed changes in clinical global impression scale using binary logistic generalised estimating 
equations regression with an exchangeable working correlation and bootstrapped standard errors. 
We analysed the number of chronic fatigue syndrome symptoms with ordinary least squares linear 
regression, and the presence of specific chronic fatigue syndrome symptoms with logistic regression. 
We analysed secondary outcomes with mixed linear regression models with random participant 
intercepts and slopes over time, apart from the walking test, which had random intercepts only. 
Covariates in the models were otherwise the same, except for clinical global impression (not 
measured at baseline) and chronic fatigue syndrome symptoms (measured only at 52 weeks). 
We excluded participants from the intention-to-treat population for whom we had no primary 
outcome data in the final analysis, which used restricted maximum likelihood. The per-protocol 
analysis excluded participants who were ineligible after randomisation, treated at a second centre, 
or did not received adequate treatment, adjusting for actual stratification factors. Statistical analyses 
were done with Stata version 10, SAS version 9.1, and SPSS version 18. 
This trial is registered at http://isrctn.org, number ISRCTN54285094. 
 
Role of the funding source 
The sponsors of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. All named authors had access to the data, commented on 
drafts, and approved the final report. Members of the writing group had responsibility for 
submitting the report, and PDW had final responsibility for the decision to submit for publication. 
 
 
Results 
Figure 1 shows the trial profile. Briefly, 898 (28%) of 3158 patients screened for eligibility progressed 
to baseline screening and 641 (71%) participants were recruited (figure 1). The commonest reason 
for exclusion from initial clinician screening was failure to meet Oxford criteria for chronic fatigue 
syndrome (1011 participants). 745 (74%) of these excluded patients did not have chronic fatigue 
syndrome and the rest did not meet Oxford criteria despite having clinician-diagnosed chronic 
fatigue syndrome. Table 1 shows baseline characteristics of participants, which were much the same 
between groups, apart from a shorter duration of illness in the SMC group than was noted in the 
other groups. 33 (5%) of 640 participants were lost to follow-up, but rates did not differ between 
groups (p=0·30; figure 1). Ten of these 33 participants had no outcome data, and were therefore 
excluded from the final analysis. Primary outcomes were assessed at the time of dropout for three 
participants and included in the final analyses. Research assessors recorded primary outcomes (eg, 
dictated over the telephone) on 74 (4%) of 1920 occasions. 
Table 2 shows details of treatments received. Participants allocated to SMC alone received more 
sessions, but there were no differences in the number of SMC sessions or therapy sessions received 
between the other three groups. There were no differences between groups in the proportions who 
had received adequate treatment (85% or more in every group). Participants' expectations were 
high for APT and GET, but lower for CBT and SMC (table 2). Most of those who received a therapy 
were satisfied with treatment (82% or more for the three therapies), but fewer were satisfied with 
SMC (50%). Number of treatment dropouts did not differ between groups (p=0·50; table 2). The two 
independent therapy assessors rated 58 (94%) of 62 and 57 (92%) of 62 therapy sessions as being 
the one allocated; only one (2%) session was rated by both assessors as different from that 
allocated. The inter-rater reliaďilitǇ ;κ; ϵϱ% CIͿ ǁas 0·86 (0·75–0·97). The independent assessors 
were unmasked in 25 (40%) of 62 sessions that they listened to. All three therapies were rated as 
adhering well to the manuals. Therapeutic alliance median scores were high and the same across 
therapies. 
Table 3 shows baseline and outcomes data, and figure 2 shows profiles for the primary outcomes. In 
the final-adjusted models (figure 3), participants had less fatigue and better physical function after 
CBT and GET than they did after APT or SMC alone. Outcomes after APT were no better than they 
were after SMC. Allowing for clustering effects caused by participants attending the same main 
praĐtitioŶer had little effeĐt oŶ these results; iŶtraĐlass ĐorrelatioŶ ĐoeffiĐieŶts raŶged froŵ −Ϭ·ϬϮ to 
0·11 for fatigue, and −Ϭ·Ϭϭ to Ϭ·Ϭϯ for phǇsiĐal fuŶĐtioŶ. PartiĐipaŶt suďgroups ŵeetiŶg iŶterŶatioŶal 
criteria for chronic fatigue syndrome, London criteria for myalgic encephalomyelitis, and depressive 
disorder criteria did not differ in the pattern of treatment effects (figure 2; all pinteractions were 
non-significant). 
64 (42%) of 153 participants in the APT group improved by at least 2 points for fatigue and at least 8 
points for physical function at 52 weeks, compared with 87 (59%) of 148 participants for CBT, 94 
(61%) of 154 participants for GET, and 68 (45%) of 152 participants for SMC. More participants 
improved after CBT compared with APT (p=0·0033) or SMC (p=0·0149), and more improved with GET 
compared with APT (p=0·0008) or SMC (p=0·0043); APT did not differ from SMC (p=0·61; 
webappendix p 2). 
25 (16%) of 153 participants in the APT group were within normal ranges for both primary outcomes 
at 52 weeks, compared with 44 (30%) of 148 participants for CBT, 43 (28%) of 154 participants for 
GET, and 22 (15%) of 152 participants for SMC. More participants were within normal ranges after 
CBT than APT (p=0·0057) or SMC (p=0·0014), and more were within normal ranges with GET 
compared with APT (p=0·0145) or SMC (p=0·0040); APT did not differ from SMC (p=0·65). 
Webappendix p 3 shows the per-protocol analysis. Differences between treatments were very 
similar to those of the final analysis, but magnitude was almost always higher in the per-protocol 
analysis. 
Table 4 shows safety outcomes. Non-serious adverse events were common. Participants who 
received CBT reported slightly fewer such events than did those in the APT (p=0·0081) and SMC 
(p=0·0016) groups. Serious adverse events and serious deterioration were uncommon; serious 
adverse reactions were rare. There were more serious adverse events in the GET group than there 
were in the SMC group (p=0·0433). Rates of serious adverse reactions and serious deterioration did 
not differ between treatment groups. Webappendix pp 4–5 shows a summary of serious adverse 
events and serious adverse reactions. 
Table 5 shows data for the clinical global impression scale ratings. At 52 weeks, more patients rated 
themselves as much better or very much better in overall health after CBT and GET than did after 
APT aŶd “MC. A ŵiŶoritǇ ;≤ϵ% iŶ eǀerǇ groupͿ rated theŵselǀes as ŵuĐh ǁorse or ǀerǇ ŵuĐh ǁorse, 
which did not differ between groups. 
Table 6 shows other secondary outcomes. At 52 weeks, participants in the CBT and GET groups had 
better outcomes than did participants in the APT and SMC groups for work and social adjustment 
scores, sleep disturbance, and depression (with the one exception that GET was no different from 
APT for depression). Anxiety was lower after CBT and GET than it was after SMC, but not than after 
APT. There were fewer chronic fatigue syndrome symptoms after CBT than there were after SMC. 
Poor concentration and memory did not differ between groups. Postexertional malaise was lower 
after CBT and GET than it was after APT and SMC. 6-min walking distances were greater after GET 
than they were APT and SMC, but were no different after CBT compared with APT and SMC. There 
were no differences in any secondary outcomes between APT and SMC groups (webappendix pp 6–
9). 
 
Discussion 
When added to SMC, CBT and GET had greater success in reducing fatigue and improving physical 
function than did APT or SMC alone. APT was no better than was SMC alone. Our findings were 
much the same for participants meeting the different diagnostic criteria for chronic fatigue 
syndrome and for myalgic encephalomyelitis, for those with depressive disorder, and after allowing 
for clustering effects. Other secondary outcomes showed a very similar pattern. There were no 
important differences in safety outcomes between treatment options. 
Mean differences between groups on primary outcomes almost always exceeded predefined 
clinically useful differences for CBT and GET when compared with APT and SMC. In all comparisons 
of the proportions of participants who had either improved or were within normal ranges for these 
outcomes, CBT and GET did better than did APT or SMC alone. No more than 30% of participants 
were within normal ranges for both outcomes and only 41% rated themselves as much better or 
very much better in their overall health. We suggest that these findings show that either CBT or GET, 
when added to SMC, is an effective treatment for chronic fatigue syndrome, and that the size of this 
effect is moderate (panel 2). 
 
[Start panel 2] 
Panel 2 
Research in context 
Systematic review 
We searched the PubMed and Cochrane Library databases up to Nov 6, 2010, without language 
restrictions for full papers reporting randomised controlled trials, systematic reviews, and meta-
aŶalǇses ǁith the searĐh terŵs ͞ĐhroŶiĐ fatigue sǇŶdroŵe͟, ͞ŵǇalgiĐ eŶĐephaloŵǇelitis͟, ͞ŵǇalgiĐ 
eŶĐephalopathǇ͟ aŶd ͞ĐogŶitiǀe ďehaǀiour therapǇ͟, ͞eǆerĐise͟, ͞paĐiŶg͟. We eǆĐluded trials of 
adolescents, education, and group interventions. Our search identified the two most recent 
systematic reviews,4,5 two meta-analyses,6,7 and two additional trials34,35 that were not included 
in these reviews. The reviews and meta-analyses concluded that cognitive behaviour therapy and 
graded exercise therapy are moderately effective treatments for chronic fatigue syndrome, and that 
limitations of previous trials included small size, an absence of data for safety outcomes, and high 
dropout rates.4–7 The findings from these studies concur with the UK National Institute for Health 
and Clinical Excellence guidelines.2 
Interpretation 
In the pacing, graded activity, and cognitive behaviour therapy: a randomised evaluation (PACE) trial, 
we affirm that cognitive behaviour therapy and graded exercise therapy are moderately effective 
outpatient treatments for chronic fatigue syndrome when added to specialist medical care, as 
compared with adaptive pacing therapy or specialist medical care alone. Findings from PACE also 
allow the following interpretations: adaptive pacing therapy added to specialist medical care is no 
more effective than specialist medical care alone; our findings apply to patients with differently 
defined chronic fatigue syndrome and myalgic encephalomyelitis whose main symptom is fatigue; 
and all four treatments tested are safe. 
[End panel 2] 
 
Our conclusions are supported by secondary outcomes, as both CBT and GET provided greater 
improvements than did APT and SMC for most outcomes. The objective walking test favoured GET 
over CBT, whereas CBT provided the largest reduction in depression. The comparatively greater 
reduction in postexertional malaise with both CBT and GET compared with the other two treatments 
is notable, since the risk of exacerbation of this symptom is commonly given as a reason to avoid 
treatments such as GET. The 47% prevalence of mood and anxiety disorders at baseline was much 
the same as that noted in previous trials in secondary care (38–56%).20,23,36 The equivalent use of 
antidepressants in the treatment groups implies that the differences in outcomes are unlikely to be 
attributable to these drugs. 
There were no differences between groups in the proportions with serious deterioration or serious 
adverse reactions. The increased rate of serious adverse events with GET compared with SMC is 
unlikely to be important because serious adverse events were not thought by the independent 
scrutinisers to be related to treatment. Consequently, if these treatments are delivered as described, 
by similarly qualified and trained clinicians, patients need not be concerned about safety.37 
The finding that APT when added to SMC was no more effective than SMC alone was contrary to our 
initial hypothesis. This finding might in part be caused by greater improvement after SMC than was 
expected. Suboptimum delivery of APT is an unlikely explanation because APT therapists were the 
most experienced; the therapeutic alliance and the adherence to manuals were rated highly in this 
group and participant satisfaction did not differ from that for other therapies. Since participants' 
confidence that APT would help them was much the same as for GET, and greater than that for CBT, 
they were unlikely to have been biased by negative expectations. The fundamental difference 
between APT and both CBT and GET is that APT encourages adaptation to the illness,13,17,18 
whereas CBT and GET encourage gradual increases in activity with the aim of ameliorating the 
illness.2,4,7 Our results do not support pacing, in the form of APT, as a first-line therapy for chronic 
fatigue syndrome. 
We plan to report relative cost-effectiveness of the treatments, their moderators and mediators, 
whether subgroups respond differently, and long-term follow-up in future publications. Our finding 
that studied treatments were only moderately effective also suggests research into more effective 
treatments is needed. The effectiveness of behavioural treatments does not imply that the condition 
is psychological in nature. 
Our findings were strengthened by the small numbers of dropouts, high rates of acceptance of the 
treatments, use of manual-defined treatments provided by competent clinicians, high rates of 
participant satisfaction, adherence to manuals, and therapeutic alliance. The PACE findings can be 
generalised to patients who also meet alternative diagnostic criteria for chronic fatigue syndrome12 
and myalgic encephalomyelitis13 but only if fatigue is their main symptom.11 
Our trial had limitations. We excluded patients unable to attend hospital. Our results apply to 
patients referred to secondary care. SMC is not the same as usual medical care that might be 
provided by a family doctor; this study was not designed to compare SMC with usual medical care. 
Although more than 3000 patients attending clinics had to be screened to identify the 641 recruited, 
the commonest reason for exclusion at screening was not having chronic fatigue syndrome. We 
chose conventional criteria for defining clinically useful differences between treatments, although 
other thresholds could have been chosen.32 SMC was not as closely monitored or supervised as the 
other therapies, and participants receiving SMC alone had more sessions than did those in the 
therapy groups; this is unlikely to have affected comparisons between the groups. Masking of 
participants or clinicians to treatment allocation was not possible, and research assessors were also 
not masked. Primary outcomes were subjective and rated by participants. While this avoided 
investigator bias, it could be subject to other biases. Although participant-rated outcome measures 
could have been affected by expectations of treatment, which were highest for APT and GET, CBT 
was one of the two most effective treatments despite lower expectations. 
Findings from the PACE trial suggest that individually delivered CBT and GET, when added to SMC, 
are more effective and as safe as APT added to SMC or SMC alone. Patients attending secondary 
care with chronic fatigue syndrome should be offered individual CBT or GET, alongside SMC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 1. CONSORT trial profile 
CFS=chronic fatigue syndrome. APT=adaptive pacing therapy. CBT=cognitive behaviour therapy. 
GET=graded exercise therapy. SMC=specialist medical care alone. The numbers of participants per 
centre ranged from 63 to 135. 
 Figure 2. Physical function subscale and fatigue questionnaire scores by treatment group 
Data are unadjusted means (95% CI). pinteraction is the p-value of the interaction between treatment 
and criteria or disorder from the adjusted model. CFS=chronic fatigue syndrome. ME=myalgic 
encephalomyelitis. (A–D) Lowest fatigue score is best. (E–H) Highest physical function score is best. 
 Figure 3. Primary outcome treatment differences for fatigue (A) and physical function (B) at 52 
weeks 
(A) Negative values for fatigue favour the first treatment group in each pair of comparisons. (B) 
Positive values for physical function favour the first treatment group in each pair of comparisons. 
APT=adaptive pacing therapy. SMC=specialist medical care. CBT=cognitive behaviour therapy. 
GET=graded exercise therapy. 
 
 
 
 
 
Table 1 
Baseline demographics and clinical characteristics 
  
Adaptive pacing 
therapy (n=159) 
Cognitive behaviour 
therapy (n=161) 
Graded exercise 
therapy (n=160) 
Specialist medical 
care alone (n=160) 
Overall 
(n=640) 
Demographic data 
Age (years) 39 (11) 39 (12) 39 (12) 37 (11) 38 (12) 
Female 121 (76%) 129 (80%) 123 (77%) 122 (76%) 495 (77%) 
White 146 (92%) 151 (94%) 148 (93%) 150 (94%) 595 (93%) 
Any ME group 
membership 31 (19%) 26 (16%) 25 (16%) 23 (14%) 105 (16%) 
Clinical data 
International CFS criteria12 
 As randomised 99 (62%) 100 (62%) 98 (61%) 100 (63%) 397 (62%) 
 Actual 107 (67%) 106 (66%) 106 (66%) 108 (68%) 427 (67%) 
London ME criteria13 
 As randomised 89 (56%) 90 (56%) 89 (56%) 89 (56%) 357 (56%) 
  
Adaptive pacing 
therapy (n=159) 
Cognitive behaviour 
therapy (n=161) 
Graded exercise 
therapy (n=160) 
Specialist medical 
care alone (n=160) 
Overall 
(n=640) 
 Actual 81 (51%) 84 (52%) 84 (53%) 80 (50%) 329 (51%) 
Any depressive disorder 
 As randomised 55 (35%) 55 (34%) 54 (34%) 55 (34%) 219 (34%) 
 Actual 54 (34%) 52 (32%) 54 (34%) 53 (33%) 213 (33%) 
Any psychiatric 
disorder* 75 (47%) 75 (47%) 73 (46%) 77 (48%) 300 (47%) 
Duration of illness 
(months) 33 (16–69) 36 (16–104) 35 (18–67) 25 (15–57) 32 (16–68) 
Body-mass index 
(kg/m2) 25·9 (5·5) 25·4 (5·2) 25·5 (4·6) 25·1 (4·5) 25·5 (5·0) 
Data are mean (SD), n (%), or median (IQR). ME=myalgic encephalomyelitis. CFS=chronic fatigue 
syndrome. 
*Psychiatric disorders included any depressive disorder and any anxiety disorder, including phobias, 
obsessive-compulsive disorder, and post-traumatic stress disorder. 
 
 
 
 
 
 
 
Table 2 
Treatment details 
 
Adaptive pacing 
therapy (n=159) 
Cognitive behaviour 
therapy (n=161) 
Graded exercise 
therapy (n=160) 
Specialist medical 
care alone (n=160) p value* 
Treatment received 
Therapy sessions 
attended† 13 (12–15) 14 (12–15) 13 (12–14) .. 0·17 
Specialist medical care 
sessions attended‡ 3 (3–4) 3 (3–4) 3 (3–4) 5 (3–6) 0·0001 
Adequate treatment§ 143 (90%) 140 (87%) 136 (85%) 142 (89%) 0·56 
Antidepressant at baseline 63 (40%) 57 (35%) 74 (46%) 66 (41%) .. 
Antidepressant at 24 
weeks¶ 53 (34%) 45 (29%) 61 (40%) 60 (39%) 0·19 
Antidepressant at 52 
weeks¶ 41 (27%) 47 (31%) 48 (31%) 61 (39%) 0·11 
Hypnotic at baseline 6 (4%) 9 (6%) 6 (4%) 5 (3%) .. 
Hypnotic at 24 weeks¶ 3 (2%) 7 (5%) 5 (3%) 6 (4%) 0·61 
Hypnotic at 52 weeks¶ 5 (3%) 4 (3%) 3 (2%) 7 (5%) 0·62 
Non-allocated treatment 8 (5%) 4 (3%) 7 (4%) 22 (14%) 0·0005 
 Adaptive pacing 
therapy (n=159) 
Cognitive behaviour 
therapy (n=161) 
Graded exercise 
therapy (n=160) 
Specialist medical 
care alone (n=160) p value* 
Dropouts from treatment 11 (7%) 17 (11%) 10 (6%) 14 (9%) 0·50 
Views before treatment 
Treatment is logical 134 (84%) 115 (71%) 135 (84%) 79 (49%) <0·0001 
Confident about treatment 114 (72%) 91 (57%) 112 (70%) 65 (41%) <0·0001 
Views after treatment 
Satisfied with treatment¶ 128 (85%) 117 (82%) 126 (88%) 76 (50%) <0·0001 
Dissatisfied with 
treatment¶ 4 (3%) 7 (5%) 2 (1%) 17 (11%) 0·0010 
Therapeutic alliance‖ 6·5 (6·0–6·5) 6·5 (5·5–6·8) 6·5 (5·5–7·0) .. 0·96 
Adherence to manual** 6·0 (6·0–6·5) 6·0 (5·0–6·5) 6·5 (6·0–6·5) .. 0·35 
 
Data are median (IQR) or n (%). 
*p values across all groups. 
Ώ86% of sessions were received face-to-face and 14% by telephone. 
ΐ94% of sessions were received face-to-face and 6% by telephone. 
§Adequate treatment was ten or more sessions of therapy or three or more sessions of specialist 
medical care alone. 
¶Percentages exclude missing data. 
‖Scored 1–7 (1=poor, 7=excellent). 
**Scored 1–7 (1=not at all, 7=very much so). 
 
 
Table 3 
Primary outcomes of fatigue and physical function 
  
Fatigue* 
 
Physical function† 
 
  
Adaptive 
pacing 
therapy 
Cognitive 
behaviour 
therapy 
Graded 
exercise 
therapy 
Specialist 
medical 
care alone 
Adaptive 
pacing 
therapy 
Cognitive 
behaviour 
therapy 
Graded 
exercise 
therapy 
Specialist 
medical 
care alone 
Baseline 28·5 (4·0); 
n=159 
27·7 (3·7); 
n=161 
28·2 (3·8); 
n=160 
28·3 (3·6); 
n=160 
37·2 
(16·9); 
n=159 
39·0 (15·3); 
n=161 
36·7 
(15·4); 
n=160 
39·2 (15·4); 
n=160 
12 weeks 24·2 (6·4); 
n=153 
23·6 (6·5); 
n=153 
22·8 (7·5); 
n=153 
24·3 (6·5); 
n=154 
41·7 
(19·9); 
n=153 
51·0 (20·7); 
n=153 
48·1 
(21·6); 
n=153 
46·6 (20·4); 
n=154 
24 weeks 23·7 (6·9); 
n=155 
21·5 (7·8); 
n=148 
21·7 (7·1); 
n=150 
24·0 (6·9); 
n=152 
43·2 
(21·4); 
n=155 
54·2 (21·6); 
n=148 
55·4 
(23·3); 
n=150 
48·4 (23·1); 
n=152 
52 weeks 23·1 (7·3); 
n=153 
20·3 (8·0); 
n=148 
20·6 (7·5); 
n=154 
23·8 (6·6); 
n=152 
45·9 
(24·9); 
n=153 
58·2 (24·1); 
n=148 
57·7 
(26·5); 
n=154 
50·8 (24·7); 
n=152 
Mean difference 
(95% CI) from 
SMC (52 weeks) 
−0·7 (−2·3 
to 0·9) 
−3·4 (−5·0 
to −1·8) 
−3·2 (−4·8 
to −1·7) .. 
−3·4 (−8·4 
to 1·6) 
7·1 (2·0 to 
12·1) 
9·4 (4·4 to 
14·4) .. 
 
Unadjusted p 
values 0·38 0·0001 0·0003 .. 0·18 0·0068 0·0005 .. 
 
Bonferroni 
adjusted p 
values 
0·99 0·0006 0·0013 .. 0·89 0·0342 0·0025 .. 
  
Fatigue* 
 
Physical function† 
 
  
Adaptive 
pacing 
therapy 
Cognitive 
behaviour 
therapy 
Graded 
exercise 
therapy 
Specialist 
medical 
care alone 
Adaptive 
pacing 
therapy 
Cognitive 
behaviour 
therapy 
Graded 
exercise 
therapy 
Specialist 
medical 
care alone 
Mean difference 
(95% CI) from 
APT (52 weeks) 
.. 
−2·7 (−4·4 
to −1·1) 
−2·5 (−4·2 
to −0·9) .. .. 
10·5 (5·4 to 
15·6) 
12·8 (7·7 
to 17·9) .. 
 
Unadjusted p 
values .. 0·0027 0·0059 .. .. 0·0002 <0·0001 .. 
 
Bonferroni 
adjusted p 
values 
.. 0·0136 0·0294 .. .. 0·0012 0·0002 .. 
Number 
improved from 
baseline‡ 
99 (65%) 113 (76%) 123 (80%) 98 (65%) 75 (49%) 105 (71%) 108 (70%) 88 (58%) 
Data are mean scores (SD) or n (%), unless otherwise stated. Comparisons of differences across 
groups made at 52 weeks are from the final adjusted models, so are slightly different from 
unadjusted values. p values for comparisons are unadjusted, with Bonferroni values adjusted for five 
comparisons for every primary outcome. 
*Chalder fatigue questionnaire (range 0–33, 0=best).15 
ΏShort form-36 physical function subscale score (range 0–100, 100=best).16 
ΐParticipants improved from baseline by two or more points for fatigue and eight or more for 
physical function. 
 
 
 
 
 
Table 4 
Safety outcomes 
  
Adaptive pacing 
therapy (n=159) 
Cognitive behaviour 
therapy (n=161) 
Graded exercise 
therapy (n=160) 
Specialist medical 
care alone (n=160) 
Non-serious adverse events 949 848 992 977 
Participants with non-serious 
adverse events 152 (96%) 143 (89%) 149 (93%) 149 (93%) 
Non-serious adverse events 
per 100 person-years 597 (559–636) 527 (492–563) 620 (582–660) 611 (573–650) 
Serious adverse events 16 8 17 7 
Participants with serious 
adverse events 15 (9%) 7 (4%) 13 (8%) 7 (4%) 
Serious adverse events per 
100 person-years 10·1 (5·8–16·3) 5·0 (2·2–9·8) 10·6 (6·2–17·0) 4·4 (1·8–9·0) 
Serious adverse reactions 2 4 2 2 
Participants with serious 
adverse reactions 2 (1%) 3 (2%) 2 (1%) 2 (1%) 
Serious adverse reactions per 
100 person-years 1·3 (0·2–4·5) 2·5 (0·7–6·4) 1·3 (0·2–4·5) 1·3 (0·2–4·5) 
Serious deterioration 
(composite)* 13 (8%) 14 (9%) 10 (6%) 15 (9%) 
  
Adaptive pacing 
therapy (n=159) 
Cognitive behaviour 
therapy (n=161) 
Graded exercise 
therapy (n=160) 
Specialist medical 
care alone (n=160) 
 
Physical functioning 
reduction 7 (4%) 5 (3%) 5 (3%) 6 (4%) 
 PCGI worse 5 (3%) 7 (4%) 1 (<1%) 10 (6%) 
 Withdrawn due to worsening 3 (2%) 0 2 (1%) 1 (<1%) 
 Serious adverse reactions 2 (1%) 3 (2%) 2 (1%) 2 (1%) 
Differences in serious deterioration 
 
Comparison with specialist 
medical care −1·2%; p=0·71 −0·7%; p=0·83 −3·1%; p=0·30 .. 
 
Comparison with adaptive 
pacing therapy .. 0·5%; p=0·87 −1·9%; p=0·51 .. 
Data are n, n (%), or rate (95% CI), unless otherwise stated. Adverse events were considered serious 
when they involved death, hospital admission, increased severe and persistent disability, self-harm, 
were life-threatening, or required an intervention to prevent one of these. There were no suspected 
unexpected serious adverse reactions. PCGI=participant-rated clinical global impression. 
*Serious deterioration composite is either of a short form-36 physical function subscale score 
reduction at two consecutive visits, a PCGI score of much worse or very much worse at two 
consecutive visits, withdrawal from treatment due to explicit worsening, or a serious adverse 
reaction; the numbers withdrawn from treatment due to worsening is a subset of all those 
withdrawing from treatment shown in table 2. 
 
 
 
 
Table 5 
Participant-rated clinical global impression of change in overall health 
  
Adaptive pacing 
therapy (n=159) 
Cognitive behaviour 
therapy (n=161) 
Graded exercise 
therapy (n=160) 
Specialist medical care 
alone (n=160) 
Change from baseline 
12 weeks 153 (96%) 153 (95%) 151 (94%) 151 (94%) 
 Positive change 20 (13%) 32 (21%) 37 (25%) 7 (5%) 
 Minimum change 126 (82%) 113 (74%) 111 (74%) 133 (88%) 
 Negative change 7 (5%) 8 (5%) 3 (2%) 11 (7%) 
24 weeks 155 (97%) 149 (93%) 148 (93%) 151 (94%) 
 Positive change 37 (24%) 56 (38%) 54 (37%) 28 (19%) 
 Minimum change 111 (72%) 82 (55%) 89 (60%) 107 (71%) 
 Negative change 7 (5%) 11 (7%) 5 (3%) 16 (11%) 
52 weeks 153 (96%) 147 (91%) 152 (95%) 152 (95%) 
 Positive change 47 (31%) 61 (41%) 62 (41%) 38 (25%) 
  
Adaptive pacing 
therapy (n=159) 
Cognitive behaviour 
therapy (n=161) 
Graded exercise 
therapy (n=160) 
Specialist medical care 
alone (n=160) 
 Minimum change 96 (63%) 77 (52%) 80 (53%) 100 (66%) 
 Negative change 10 (7%) 9 (6%) 10 (7%) 14 (9%) 
Odds ratio (positive change vs negative or minimum changes) 
Compared with specialist 
medical care 1·3 (0·8–2·1); p=0·31 2·2 (1·2–3·9); p=0·011 
2·0 (1·2–3·5); 
p=0·013 .. 
Compared with adaptive 
pacing therapy .. 1·7 (1·0–2·7); p=0·034 
1·5 (1·0–2·3); 
p=0·028 .. 
Data are n (%) or odds ratio (95% CI). Comparisons made at 52 weeks were taken from the final 
adjusted models. Positive change was defined as very much better or much better. Minimum change 
was defined as a little better, no change, or a little worse. Negative change was defined as much 
worse or very much worse. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6 
Secondary outcomes 
  
Adaptive pacing 
therapy (n=159) 
Cognitive behaviour 
therapy (n=161) 
Graded exercise 
therapy (n=160) 
Specialist medical care 
alone (n=160) 
Work and social adjustment 
scale 150 (94%) 143 (89%) 144 (90%) 151 (94%) 
 Baseline score 27·9 (6·1) 27·4 (6·2) 27·3 (6·3) 26·9 (6·7) 
 52-week score 24·5 (8·8) 21·0 (9·6) 20·5 (9·4) 23·9 (9·2) 
 Comparison with SMC 0·1; p=0·93 −3·6; p=0·0001 −3·2; p=0·0006 .. 
 Comparison with APT .. −3·7; p=0·0001 −3·3; p=0·0004 .. 
6-min walking test 111 (70%) 123 (76%) 110 (69%) 118 (74%) 
 Baseline distance (m) 314 (90) 333 (86) 312 (87) 326 (95) 
 52-week distance (m) 334 (117) 354 (106) 379 (100) 348 (108) 
 Comparison with SMC −5·7; p=0·55 −1·5; p=0·87 35·3; p=0·0002 .. 
 Comparison with APT .. 4·2; p=0·65 41·0; p<0·0001 .. 
Jenkins sleep scale 150 (94%) 143 (89%) 144 (90%) 151 (94%) 
  
Adaptive pacing 
therapy (n=159) 
Cognitive behaviour 
therapy (n=161) 
Graded exercise 
therapy (n=160) 
Specialist medical care 
alone (n=160) 
 Baseline score 12·1 (4·9) 12·5 (4·9) 11·7 (4·3) 12·4 (5·0) 
 52-week score 10·6 (4·8) 9·9 (5·3) 9·0 (4·8) 11·0 (5·0) 
 Comparison with SMC −0·1; p=0·76 −1·1; p=0·0216 −1·4; p=0·0024 .. 
 Comparison with APT .. −0·9; p=0·0466 −1·3; p=0·0062 .. 
HADS depression scale 149 (94%) 143 (89%) 144 (90%) 151 (94%) 
 Baseline score 8·1 (3·9) 8·3 (3·7) 8·2 (3·6) 8·0 (3·9) 
 52-week score 7·2 (4·5) 6·2 (3·7) 6·1 (4·1) 7·2 (4·7) 
 Comparison with SMC −0·6; p=0·11 −1·4; p=0·0003 −1·1; p=0·0035 .. 
 Comparison with APT .. −0·8; p=0·0382 −0·5; p=0·18 .. 
HADS anxiety scale 149 (94%) 143 (89%) 144 (90%) 149 (93%) 
 Baseline score 8·1 (4·2) 8·1 (4·3) 8·0 (4·2) 7·9 (4·3) 
 52-week score 7·5 (4·2) 6·8 (4·2) 7·1 (4·5) 8·0 (4·4) 
  
Adaptive pacing 
therapy (n=159) 
Cognitive behaviour 
therapy (n=161) 
Graded exercise 
therapy (n=160) 
Specialist medical care 
alone (n=160) 
 Comparison with SMC −0·7; p=0·0713 −1·4; p=0·0003 −1·0; p=0·0142 .. 
 Comparison with APT .. −0·7; p=0·0671 −0·3; p=0·50 .. 
Chronic fatigue syndrome 
symptom count 151 (95%) 145 (90%) 144 (90%) 149 (93%) 
 Baseline 4·8 (1·8) 4·6 (1·8) 4·6 (1·8) 4·7 (1·7) 
 52 week 3·8 (2·3) 3·4 (2·3) 3·4 (2·5) 3·9 (2·2) 
 Comparison with SMC −0·1; p=0·62 −0·5; p=0·0329 −0·4; p=0·0916 .. 
 Comparison with APT .. −0·4; p=0·0986 −0·3; p=0·23 .. 
Poor concentration or 
memory 151 (95%) 145 (90%) 144 (90%) 149 (93%) 
 
Baseline (n [%] with 
symptoms) 122 (77%) 117 (73%) 122 (76%) 115 (72%) 
 
52 weeks (n [%] with 
symptoms) 93 (59%) 73 (45%) 76 (48%) 90 (56%) 
 Comparison with SMC Odds ratio 1·0; p=0·97 
Odds ratio 0·6; 
p=0·0602 
Odds ratio 0·7; 
p=0·14 .. 
  
Adaptive pacing 
therapy (n=159) 
Cognitive behaviour 
therapy (n=161) 
Graded exercise 
therapy (n=160) 
Specialist medical care 
alone (n=160) 
 Comparison with APT .. Odds ratio 0·6; p=0·0629 
Odds ratio 0·7; 
p=0·15 .. 
Postexertional malaise 151 (95%) 145 (90%) 144 (90%) 149 (93%) 
 
Baseline (n [%] with 
symptoms) 134 (84%) 135 (84%) 131 (82%) 139 (87%) 
 
52 weeks (n [%] with 
symptoms) 100 (63%) 79 (49%) 71 (44%) 101 (63%) 
 Comparison with SMC Odds ratio 1·0; p=0·86 
Odds ratio 0·6; 
p=0·0254 
Odds ratio 0·5; 
p=0·0026 .. 
 Comparison with APT .. Odds ratio 0·6; p=0·0380 
Odds ratio 0·5; 
p=0·0042 .. 
Data are number of completed questionnaires at 52 weeks (%), means (SD), or mean difference, 
unless otherwise stated. Comparisons across treatment arms at 52 weeks are from the final adjusted 
models. Webappendix pp 6–9 shows forest plots of mean differences (95% CI) and odds ratios (95% 
CI) for comparisons between groups. APT=adaptive pacing therapy. SMC=specialist medical care 
alone. HADS=hospital anxiety and depression scale. 
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